Cadrenal Therapeutics still not in compliance with Nasdaq minimum bid price; requests extension

Cadrenal Therapeutics, Inc.

Received Nasdaq deficiency letter on Sept 6, 2023 for bid price below $1.00 for 30 consecutive business days.
Stock traded above $1.00 for 14 consecutive days Jan 19-Feb 7, 2024, but Nasdaq has not confirmed compliance.
Company intends to request an additional 180-day compliance period under Nasdaq rules.
If compliance not regained, delisting notice would trigger a hearing; reverse stock split considered as option.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.